» Articles » PMID: 31228799

HIF-1α Induced Long Noncoding RNA FOXD2-AS1 Promotes the Osteosarcoma Through Repressing P21

Overview
Date 2019 Jun 23
PMID 31228799
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Emerging literature indicates the essential roles of long noncoding RNA (lncRNA) in the osteosarcoma (OS). However, the regulatory function and mechanism of FOXD2-AS1 in the OS is still elusive. In present research, the level of FOXD2-AS1 was significantly up-regulated in the OS tissue and cell lines compared to corresponding controls. The aberrant high-expression of FOXD2-AS1 indicated the poor clinical prognosis of OS patients. Transcription factor HIF-1α could bind with the promoter region of FOXD2-AS1 to activate the transcription in OS cells. Functionally, the knockdown of FOXD2-AS1 could repress the malignant biological properties of OS cells in vitro and vivo, including proliferation, invasion, apoptosis and tumor growth. Mechanistically, FOXD2-AS1 inhibited the expression of p21 via interacting with EZH2 to silence p21 gene expression. Overall, we conclude that FOXD2-AS1, induced by transcription factor HIF-1α, acts as an oncogene in the OS tumorigenesis and FOXD2-AS1 interacts with EZH2 to silence p21 protein. This finding could provide a novel insight and potential therapeutic target for the OS.

Citing Articles

LncRNAs as potential prognosis/diagnosis markers and factors driving drug resistance of osteosarcoma, a review.

Hu S, Han X, Liu G, Wang S Front Endocrinol (Lausanne). 2024; 15:1415722.

PMID: 39015175 PMC: 11249743. DOI: 10.3389/fendo.2024.1415722.


Hypoxia makes EZH2 inhibitor not easy-advances of crosstalk between HIF and EZH2.

Huang Z, Tang Y, Zhang J, Huang J, Cheng R, Guo Y Life Metab. 2024; 3(4.

PMID: 38911968 PMC: 11192520. DOI: 10.1093/lifemeta/loae017.


Hypoxia inducible factor-1ɑ as a potential therapeutic target for osteosarcoma metastasis.

Zhou J, Lan F, Liu M, Wang F, Ning X, Yang H Front Pharmacol. 2024; 15:1350187.

PMID: 38327979 PMC: 10847273. DOI: 10.3389/fphar.2024.1350187.


Research progress in the mechanism and treatment of osteosarcoma.

Bian J, Liu Y, Zhao X, Meng C, Zhang Y, Duan Y Chin Med J (Engl). 2023; 136(20):2412-2420.

PMID: 37649421 PMC: 10586865. DOI: 10.1097/CM9.0000000000002800.


Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma.

Xia Y, Wang D, Piao Y, Chen M, Wang D, Jiang Z Front Immunol. 2022; 13:1025532.

PMID: 36457998 PMC: 9705758. DOI: 10.3389/fimmu.2022.1025532.